Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: A systematic review

PharmacoEconomics

Volumn 28, Issue 9, 2010, Pages 781-782

  Plumb, Jonathan M ^a   Clemens, Andreas ^a   Monz, Brigitta U ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Anticoagulants, therapeutic use; Antithrombotics, therapeutic use; Cost effectiveness; Dabigatran etexilate, therapeutic use; Dalteparin sodium, therapeutic use; Deep vein thrombosis, Prevention; Enoxaparin sodium, therapeutic use; Factor Xa inhibitors, therapeutic use; Fondaparinux sodium, therapeutic use; Low molecular weight heparins, therapeutic use; Pulmonary embolism, Prevention; Rivaroxaban, therapeutic use

Indexed keywords

DABIGATRAN; ENOXAPARIN; RIVAROXABAN;

BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; PRIORITY JOURNAL; SYSTEMATIC REVIEW; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTITHROMBINS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BENZIMIDAZOLES; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; ENOXAPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MODELS, ECONOMIC; MORPHOLINES; POLYSACCHARIDES; POSTOPERATIVE COMPLICATIONS; PYRIDINES; QUALITY-ADJUSTED LIFE YEARS; THIOPHENES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 77956250079     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11535700-000000000-00000     Document Type: Letter

References (15)

1. Kapoor A, Chuang W, Radhakrishnan N, et al. Cost effec-tiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review. Pharmacoeconomics 2010; 28 (7): 521-538
2. National Institute for Health and Clinical Excellence. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. Technology appraisal guidance 1 London: NICE, 2008 Sep National Institute for Health and Clinical Excellence. Riv-aroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults. Technology appraisal guidance 1 London: NICE, 2009 Apr Scottish Medicines Consortium. Drug advice: dabigatran etexilate, 75mg and 110mg hard capsules (Pradaxa®). Glasgow: SMC, 2008 May Scottish Medicines Consortium. Drug advice: rivaroxaban 10 mg film-coated tablets (Xarelto®). Glasgow: SMC, 2008 Nov
3. Wolowacz SE, Roskell NS, Maciver F, et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism following total knee and hip replacement surgery. Clin Ther 2009; 31 (1): 194-212
4. Wolowacz SE, Roskell NS, Plumb JM, et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. Thromb Haemost 2010; 103 (2): 360-371
5. Wolowacz SE, Hess N, Brennan VK, et al. Cost-effectiveness of venous thromboembolism prophylaxis in total hip and knee replacement surgery: the evolving application of health economic modelling over 20 years. Curr Med Res Opin 2008 Oct; 24 (10): 2993-3006
6. McCullagh L, Tilson L, Walsh C, et al. A cost-effectiveness analysis model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics 2009; 27 (10): 829-846
7. Kakkar AK, Brenner B, Dahl OE, et al., RECORD2 Investi-gators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembo-lism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372 (9632): 31-39
8. Lassen MR. Recent developments in the use of oral antic-oagulants. Expert Opin Pharmacother 2009; 10 (11): 1769-1781
9. Gomez-Outes A, Lecumberri R, Pozo C, et al. New anti-coagulants: focus on venous thromboembolism. Curr Vasc Pharmacol 2009; 7 (3): 309-329
10. Merli G, Spyropoulos AC, Caprini JA. Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations. Ann Surg 2009; 250 (2): 219-228
11. Hull RD, Yusen RD, Bergqvist D. State-of-the-art review: assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis. Clin Appl Thromb Hemost 2009; 15 (4): 377-388
12. Eriksson BI, Dahl OE, Rosencher N, et al., RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370 (9591): 949-956
13. Eriksson BI, Borris LC, Friedman RJ, et al., RECORD1 Study Group. Rivaroxaban versus enoxaparin for thrombo-prophylaxis after hip arthroplasty. N Engl J Med 2008; 358 (26): 2765-2775
14. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5 (11): 2178-2185
15. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee ar-throplasty. N Engl J Med 2008; 358 (26): 2776-86